Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year High – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $26.34 and last traded at $26.04, with a volume of 200242 shares changing hands. The stock had previously closed at $25.83.

Analysts Set New Price Targets

TYRA has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Wedbush increased their price objective on shares of Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Raymond James Financial started coverage on shares of Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Tyra Biosciences Trading Down 0.3%

The company has a market cap of $1.39 billion, a P/E ratio of -13.88 and a beta of 1.09. The company has a 50 day moving average price of $19.30 and a 200-day moving average price of $14.21.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Equities analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the transaction, the director directly owned 3,823,425 shares in the company, valued at approximately $95,585,625. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.20% of the stock is owned by corporate insiders.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. raised its holdings in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after acquiring an additional 1,668 shares during the period. SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences during the third quarter valued at approximately $133,000. Public Employees Retirement System of Ohio bought a new stake in Tyra Biosciences during the 2nd quarter valued at $177,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Tyra Biosciences by 27.7% during the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.